Alvotech ALVO

NAS: ALVO | ISIN: LU2458332611   19/11/2025
5,230 USD (+2,35%)
(+2,35%)   19/11/2025
Grafiek Alvotech Grafiek Alvotech

Alvotech in het nieuws

20 november 2025 · Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab) · Persbericht

13 november 2025 · Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman · Persbericht

12 november 2025 · Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update · Persbericht

10 november 2025 · UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)          · Persbericht

6 november 2025 · Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA · Persbericht

4 november 2025 · Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update · Persbericht

2 november 2025 · Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05 · Persbericht

22 oktober 2025 · Alvotech Announces Changes in Global Business Development and Commercial Operations Team · Persbericht

6 oktober 2025 · European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency · Persbericht

22 september 2025 · European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva® · Persbericht

Mijn selecties